香港股市 將在 13 分鐘 開市

MRK Feb 2023 100.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
6.18+1.58 (+34.35%)
市場開市。 截至 03:53PM EST。
全螢幕
前收市價4.60
開市5.91
買盤5.95
賣出價6.20
拍板100.00
到期日2023-02-17
今日波幅5.91 - 6.18
合同範圍
成交量6
未平倉合約1.38k
  • AASTOCKS

    《大行報告》高盛上調默沙東(MRK.US)目標價至120美元 評級「買入」

    高盛發表研究報告指,默沙東(MRK.US)日前公布去年第四季業績,績後股價表現跑輸大市,認為是一個較吸引的買入機會,目標價由118美元上調至120美元。 該行指出,癌症免疫療法單抗Keytruda的銷售額略低於該行及市場預期,但該產品近日於非小細胞肺癌(NSCLC)輔助治療方面獲批,管理層預期增長將會循序漸進。 高盛又指,默沙東對疫苗業務的前景持積極態度,在產能提升下Gardasil(子宮頸癌疫苗)今年增長速度將加快。憧憬即將舉行的美國心臟病學學院(ACC)會議上分享的重要臨床數據、已商業化產品持續釋放潛力,以及公司過往的穩健財政能力,將繼續帶來增長動力,同時預期默沙東在業務發展及併購方面的資本配置戰略,將為股東帶來價值,預測今年將進行約40億美元的回購,重申「買入」評級並列入確信買入名單。(gc/u)~ 阿思達克財經新聞 網址: www.aastocks.com

  • Insider Monkey

    12 Safe Stocks to Buy For Long-Term

    In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain […]

  • Benzinga

    Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients

    Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued